Fig. 5

PEGDA–PLL implants program host T-cells leading to reduction of tumor size in vivo. a Experimental design for anti-tumor study conducted in C57BL/6 mice bearing B16-OVA melanoma tumor, with bolus (B16-OVA + BLV) or PEGDA–PLL (B16-OVA + SLV) matrices immobilized with OVA-TCR encoding lentiviruses (LVs). b Mean tumor volume measured for treatment as well as the untreated (B16-OVA) groups. c Comparison of tumors explanted on day 20 from various treatment groups. d Change in body weight for each treatment group. e Mean tumor volume measured for GFP expressing lentivirus loaded implant (GFP-SLV) as well as the untreated (B16-OVA) groups. f Comparison of tumors explanted on day 20 from various treatment groups. Red cross indicated that the corresponding animal died before the time-point was reached. Minimum unit of scale is 1 mm. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, one-way ANOVA with Tukey’s test. PEGDA–PLL polyethylene glycol diacrylate poly-L-lysine OVA-TCR ovalbumin T-cell receptor, BLV bolus lentiviruses, SLV scaffold loaded lentiviruses, GFP green fluorescent protein